In addition, since the NAC-treated group also has a low side effect profile compared to other groups, tests should be conducted to assess the effect of this drug as single-drug therapy in the future instead of being used as an adjuvant to other medications
Statistical analysis revealed significant differences in CNV profiles across 17 distinct tumor types, including glioblastoma multiforme (Neutral = 146, Gain = 3, p = 0.03), GMBLGG (Neutral = 649, Gain = 7, p = 6.2e3), CESC (Neutral = 278, Gain = 10, Loss = 4, p = 0.02), LUAD (Neutral = 465, Gain = 39, Loss = 7, p = 8.3e5), COADREAD (Neutral = 362, Gain = 14, p = 3.9e3), BRCA (Neutral = 987, Loss = 27, Gain = 69, p = 7.3e8), ESCA (Neutral = 154, Gain = 21, Loss = 5, p = 2.6 e3), STES (Neutral = 525, Gain = 52, Loss = 14, p = 5.3e-11), SARC (Neutral = 240, Gain = 9, Loss = 8, p = 4.2e3), STAD (Neutral = 371, Gain = 31, Loss = 9, p = 3.9e8), HNSC (Neutral = 490, Loss = 10, Gain = 12, p = 1.6e4), LUSC (Neutral = 459, Loss = 18, Gain = 20, p = 1.4e7), LIHC (Neutral = 352, Loss = 3, Gain = 12, p = 0.02), READ (Neutral = 85, Gain = 6, p = 1.1e3), OV (Neutral = 337, Gain = 58, Loss = 21, p = 3.7e6), UVM (Neutral = 76, Gain = 3, p = 0.03), and BLCA (Neutral = 362, Gain = 32, Loss = 11, p = 7.6e6) ( Figure 3C )
TRMA is an autosomal recessive disease associated with megaloblastic anemia, diabetes mellitus, and sensorineural deafness
Assay: GSH/GSSG in mice stromal cells
"Protein, carbohydrates, and fats: Energy metabolism." Sustained Energy for Enhanced Human Functions and Activity
